Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 11, 2009, Pages 1805-1810

  Beddhu, Srinivasan ^a,b   Ma, Xiulian ^b   Baird, Bradley ^b   Cheung, Alfred K ^a,b   Greene, Tom ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMLODIPINE; CALCIUM; METOPROLOL; PHOSPHORUS; RAMIPRIL;

ADULT; AFRICAN AMERICAN; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHOSPHATE BLOOD LEVEL;

ADULT; AFRICAN AMERICANS; AGED; ALKALINE PHOSPHATASE; CALCIUM; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHOSPHORUS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 73449083385     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01560309     Document Type: Article

References (14)

1. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC: Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcification. Kidney Int 73: 1024-1030, 2008
2. Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts MF, Millan JL: Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 22: 1700-1710, 2007
3. Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2: 1241-1248, 2007
4. Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K: Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 17: 38-44, 2007
5. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A, Akiba T, Keen ML, Young EW, Port FK: High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 75: 1114, 2009
6. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
7. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER III, Norris K, O'Connor D, Ojo A, Phillips RA, Poque V, Rahman M, Randall OS, Rostrand S, Schulman G, Smith W, Thornely-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S, African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719-2728, 2001
8. Wright JT, Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Herbert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostrand SG; African American Study of Kidney Disease and Hypertension Study: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288: 2421-2431, 2002
9. Fadini GP, Pauletto P, Avogaro A, Rattazzi M: The good and the bad in the link between insulin resistance and vascular calcification. Atherosclerosis 193: 241-244, 2007
10. Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH: Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 23: 1850-1858, 2008
11. Cheung BM, Ong KL, Cheung RV, Wong Ly, Wat NM, Tam S, Leung GM, Cheng CH, Woo J, Janus ED, Lau CP, Lam TH, Lam KS: Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese. Clin Chem Lab Med 46: 523-527, 2008
12. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, Levy Y, Brook GJ Anoson D: Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 25: 193-197, 2005
13. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Jr., Haffner SM: Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes 54: 3140-3147, 2005
14. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriauz C, Mayor B, Chazot C: Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: Effects on mineral metabolism and bone markers. Nephrol Dial Transplant 23: 3670-3676, 2008